Evidence map›Paper›PMID 26354062›Full record

ArticleThe Korean journal of internal medicine2015

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.

Cheolsu Kim, Ho Sup Lee, Chang-Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Recent advances in multiple myeloma: a Korean perspective.The Korean journal of internal medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Cheolsu KimDepartment of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Ho Sup LeeDepartment of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Chang-Ki MinDepartment of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Je Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Kihyun KimDepartment of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hyeon Seok EomDepartment of Internal Medicine, National Cancer Center, Goyang, Korea.
Hyewon LeeDepartment of Internal Medicine, National Cancer Center, Goyang, Korea.
Won Sik LeeDepartment of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Ho-Jin ShinDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Ji Hyun LeeDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Yong ParkDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, Ulsan, Korea.
Young Rok DoDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Yeung-Chul MunDepartment of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT).

methodsData from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013.

resultsThe median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 10(9)/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively).

conclusionsPatients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.

Indexed as

AdultAgedAntineoplastic AgentsBiomarkers, TumorChemotherapy, AdjuvantDisease-Free SurvivalFemaleHospitals, UniversityHumansInduction ChemotherapyInflammation MediatorsKaplan-Meier EstimateMaleMiddle AgedMultiple MyelomaMultivariate AnalysisAntineoplastic AgentsBiomarkers, TumorInflammation MediatorsThalidomideInflammationMultiple myelomaPrognosisThalidomide

Identifiers

PMID26354062
PMCPMC4578032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.